Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

297 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T; EUROFORS Investigators. Obermayer-Pietsch BM, et al. Among authors: audran m. J Bone Miner Res. 2008 Oct;23(10):1591-600. doi: 10.1359/jbmr.080506. J Bone Miner Res. 2008. PMID: 18505369 Free article. Clinical Trial.
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC. Eastell R, et al. Among authors: audran m. J Bone Miner Res. 2009 Apr;24(4):726-36. doi: 10.1359/jbmr.081215. J Bone Miner Res. 2009. PMID: 19049337 Free article. Clinical Trial.
Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.
Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen S. Kaufman JM, et al. Among authors: audran m. J Clin Endocrinol Metab. 2013 Feb;98(2):592-601. doi: 10.1210/jc.2012-3048. Epub 2013 Jan 22. J Clin Endocrinol Metab. 2013. PMID: 23341486 Free article. Clinical Trial.
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Reid DM, et al. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140-6736(09)60250-6. Lancet. 2009. PMID: 19362675 Clinical Trial.
Background for studies on the treatment of male osteoporosis: state of the art.
Kaufman JM, Johnell O, Abadie E, Adami S, Audran M, Avouac B, Sedrine WB, Calvo G, Devogelaer JP, Fuchs V, Kreutz G, Nilsson P, Pols H, Ringe J, Van Haelst L, Reginster JY. Kaufman JM, et al. Among authors: audran m. Ann Rheum Dis. 2000 Oct;59(10):765-72. doi: 10.1136/ard.59.10.765. Ann Rheum Dis. 2000. PMID: 11005775 Free PMC article. Review.
Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis.
Compston JE, Audran M, Avouac B, Bouvenot G, Devogelaer J, Eastell R, Fabris F, Gennari C, Jones EA, Kaufman JM, Lemmel E, Mazzuoli G, Reid DM, Ringe JD, Vanhaelst L, Ziegler R, Reginster JY. Compston JE, et al. Among authors: audran m. Calcif Tissue Int. 1996 Nov;59(5):323-7. doi: 10.1007/s002239900134. Calcif Tissue Int. 1996. PMID: 8849396 No abstract available.
297 results